http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_75d07c9f60d523c6948228f8bfb2340a
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Colombo |
| name | Mario P. Colombo Mario P Colombo |
| given-name | Mario P Mario P. |
| organization-name | Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy Department of Oncology and Surgical Sciences, Oncology Section, Padua University, 35128 Padua, Italy; NicOx, 06906 Sophia Antipolis, France; Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, 20133 Milan, Italy; and Department of Oncology and Neurosciences, G. D'Annunzio University, 66013 Chieti, Italy §Istituto Nazionale Tumori, Milan, Italy 6Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS “Istituto Nazionale dei Tumori,” Milan, Italy. Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico “Istituto Nazionale dei Tumori,” Milan, Italy Department of Experimental Oncology and Molecular Medicine Fondazione IRCCS Istituto Nazionale Tumori Milan Italy *Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy 2Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milano, Italy 1Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Authors' Affiliations: 1Institut National de la Sante et de la Recherche Medicale UMR 576 and 2CHU Nice, Hopital de l'Archet, Laboratoire d'Immunologie, Nice, France; 3Université de Nice Sophia-Antipolis, UFR Sciences, Nice, France; 4Laboratorio di Oncologia Sperimentale, Istituti Ortopedici Rizzoli, Bologna, Italy; and 5Molecular Immunology Division, Department of Experimental Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy 3Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Fondazione Istituti Di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy Department of Experimental Oncology, Istituto Nazionale Tumori, via Venezian 1, 20133, Milan, Italy; and Kimmel Cancer Center, Jefferson Medical College, Philadelphia, PA 19107 §Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy ‡Unità di Immunologia Molecolare, Dipartimento di Oncologia Sperimentale e Medicina Molecolare, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, 20133 Milan, Italy; Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy 1Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. From the Unit for the Study of Disorders of Iron Metabolism, Department of Internal Medicine, University of Modena and Reggio Emilia, Modena; Immunotherapy and Gene Therapy Unit, Istituto Nazionale Tumori, Milano, Italy; Division of Microbiology, GBF–National Research Center for Biotechnology, Braunschweig, Germany; Institute of Molecular Medicine, Oxford University, John Radcliffe Hospital, Oxford, United Kingdom. §Immunotherapy and Gene Therapy Unit, Istituto Nazionaletumori, Milan, Italy 3Department of Experimental Oncology, Immunotherapy and Gene Therapy Unit, Istituto Nazionale Tumori, Milan, Italy; and From the Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; the Department of Microbiology and Immunology, University of California, San Francisco; and Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, OR. *Experimental Oncology D,; Divisions of Authors' Affiliations: 1Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; 2Department of Human Pathology, University of Palermo, Palermo, Italy; and 3Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland From the Division of Experimental Oncology D, Istituto Nazionale per Lo Studio e la Cura dei Tumori, Milano, Italy; and the Division of Microbiology, GBF-National Research Centre for Biotechnology, Braunschweig, Germany. Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milano, Italy Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy; Authors' Affiliations: 1C. Gandini Medical Oncology, Bone Marrow Transplantation Unit, 2Molecular Targeting Unit, 3Proteomics Laboratory, Department of Experimental Oncology, 4Pathology Unit, and 5Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Fondazione Istituti di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale per lo Studio e la Cura dei Tumori; and 6School of Medical Oncology, University of Milan, Milan, Italy 1Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy and Immunotherapy and Gene Therapy Unit, National Cancer Center, Milano, Italy 1Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy Authors' Affiliations: 1Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan; and 2Department of Human Pathology, University of Palermo, Palermo, Italy Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS “Istituto Nazionale dei Tumori,” Milan 20133, Italy Molecular Immunology Unit, Department of Experimental Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan; ∥Division of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy aFrom the Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy Units of Immunotherapy of Human Tumors and Gene Therapy, Istituto Nazionale Tumori, Milan, 20133 Italy Division of Experimental Oncology D, Istituto Nazionale Tumori, 20133 Milan, Italy 1Immunotherapy and Gene Therapy Unit, Istituto Nazionale Tumori and Unit of Immunotherapy of Human Tumors, Dept. of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy 1Department of Experimental Oncology, Immunotherapy and Gene Therapy Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori; Immunotherapy and Gene Therapy Unit, National Cancer Center, Milan, Italy; From the Division of Experimental Oncology D and A Istituto Nazionale Tumori, Milano; the Institute of Immunology and Infection Diseases, University of Verona, Italy; and Behringwerke AG, Marburg, Germany. Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano 5Immunotherapy and Gene Therapy Unit, Istituto Nazionale Tumori, Milan, Italy 1Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Fondazione Istituto Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy and 2Immunotherapy and Gene Therapy Unit, Istituto Nazionale dei Tumori; Molecular Immunology Unit Department of Research Fondazione IRCCS Istituto Nazionale Tumori Milano Italy 1Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. From the Department of Oncology and Neurosciences, G. d'Annunzio University of Chieti, Chieti, Italy; Department of Clinical and Biological Sciences, University of Torino, Orbassano, Italy; Institute for Cancer Research, University of Bologna, Bologna, Italy; Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; and Department of Experimental Medicine and Biochemistry, University of Tor Vergata, Rome, Italy. ‡Dipartimento di Oncologia Sperimentale e Medicina Molecolare, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico “Istituto Nazionale dei Tumori,” 20133 Milan, Italy Molecular Immunology Unit Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori Milan Italy 4Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. §Istituto Nazionale Tumori, Milan, Italy; and From the *Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy; the ‡Institute for Cancer Research, University of Bologna, 40126 Bologna, Italy; the §IST Biotechnology Satellite Unit of Bologna, 40126 Bologna, Italy; the ‖Department of Oncology and Neuroscience, G. d'Annunzio University, 66013 Chieti, Italy; the ¶National Tumor Institute, 20133 Milan, Italy; and the **Genetics Institute, Cambridge, Massachusetts 02140 2Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. ‡Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy; and 7Immunotherapy and Gene Therapy Unit, National Cancer Institute, I-20133 Milan, Italy Department of Research, Fondazione IRCCS Istituto Nazionale Tumori From the *Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy; and the ‡Department of Experimental Medicine and Pathology, Second Chair of Pathology, University of Rome “La Sapienza”, 00100 Rome, Italy 4Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. 3Immunotherapy and Gene Therapy Unit, Istituto Nazionale dei Tumori, 20133 Milan, Italy Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione Instituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori , Milano, Italy Authors' Affiliations: 1Molecular Immunology Unit, 2Molecular Targeting Unit, and 3Molecular Therapies Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan; 4Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo; 5Hematopathology Section, Department of Hematology and Oncology L. and A. Seràgnoli, S. Orsola-Malpighi Hospital, University of Bologna, Bologna; and 6Human Anatomy Section, Department of Experimental Medicine, University of Genova, Genova, Italy Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, 20133, Milano, Italy Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, 20133 Milan, Italy 3 3Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. *Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; and 2Immunotherapy and Gene Therapy, 2Immunotherapy and Gene Therapy Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy From the Immunotherapy and Gene Therapy Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy. Immunotherapy and Gene Therapy Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione Istituti di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy; 1Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. Experimental Oncology Department, Istituto Nazionale Tumori From the Immunotherapy and Gene Therapy Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy, and the Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy. Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy |
Incoming Links
Total number of triples: 281.